Chiltrem Early Phase has been fully integrated

Announced today in this Market Watch article, Chiltrem, a contract research organization, has been able to integrate their two early phase units into one cohesive unit: Chiltrem Early Phase. This was needed after the acquisition of Drug Development Solutions this past February.

Dr Brian Sanderson, Medical Director of Chiltern Early Phase had this to say:

"I am delighted to see the integration completed so thoroughly and ahead of schedule. We are now looking to build on our units' long histories of good science and medicine, both in the areas where we have traditionally been strong but also in new areas of specialization such as diabetes and cardiovascular medicine. We are also looking forward to forging academic links to provide specialist studies involving new biomarkers."